Equities

Kontigo Care AB

Kontigo Care AB

Actions
  • Price (SEK)2.10
  • Today's Change-0.02 / -0.94%
  • Shares traded6.35k
  • 1 Year change-25.00%
  • Beta0.4553
Data delayed at least 15 minutes, as of Jul 25 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kontigo Care AB is a Sweden-based company, which is primarily focused on advanced medical equipment industry. The Company operates as a provider of mobile solutions for the treatment of alcoholism. The Company develops TripleA which is a system of care for the treatment of alcoholism. The system consists of a wireless breathalyzer, an application and a health care portal. The portal creates patient care plan and shares it with health care provider. On the basis of this plan, the patient receives information about scheduled sobriety test. Test results are then sent back to the health care provider who can monitor the patient's sobriety every day. The Company operates domestically on the territory of Sweden.

  • Revenue in SEK (TTM)29.47m
  • Net income in SEK775.00k
  • Incorporated2013
  • Employees10.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chordate Medical Holding AB (publ)1.11m-28.09m36.12m3.00--1.30--32.44-0.0906-0.09060.00360.05680.0289-0.37089.70371,183.30-72.99-91.98-86.88-122.85160.96209.52-2,522.81-3,295.753.43--0.00--799.630.6511-4.45------
Scandinavian ChemoTech AB4.11m-19.26m42.30m6.00--4.60--10.28-1.28-1.280.26410.4240.23270.32241.36685,500.00-108.95-87.29-108.95-118.5539.00252.05-468.27-2,122.77---15.730.00--496.6219.137.28------
Inhalation Sciences Sweden AB18.19m-3.27m46.41m8.00--3.82--2.55-0.21-0.211.320.80141.160.94137.492,273,250.00-20.80-27.93-35.65-43.8281.2571.13-17.96-48.022.68-2.920.071--43.5526.3360.87------
Glycorex Transplantation AB (publ)31.00m-29.54m56.47m15.00--1.46--1.82-0.40-0.400.41970.54850.39780.72834.601,347,652.00-37.91-11.30-47.48-13.1784.7991.60-95.30-33.241.20-118.900.2046---17.04-2.15-254.06---0.5593--
ProstaLund AB20.12m-18.55m59.06m6.00--0.757--2.94-0.2436-0.24360.26380.6340.39120.432511.14---36.07-29.14-40.73-35.0171.0575.26-92.21-68.941.90-126.960.0255--27.5410.36-53.27--20.35--
iZafe Group AB5.00m-32.78m64.90m7.00--2.98--12.97-0.133-0.1330.02010.07910.1091.242.46714,857.10-71.38-52.17-82.09-69.40-10.99---655.02-487.500.6947--0.1174--149.93-24.79-36.76---41.66--
Kontigo Care AB29.47m775.00k67.94m10.0064.611.9014.952.310.03280.03281.171.120.6807--7.69--1.79-0.42142.55-0.619568.8466.312.63-0.5205--4.000.093--1.8016.95-92.68--44.94--
Immunovia AB (publ)1.21m-260.73m72.01m11.00--1.65--59.41-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Codelab Capital AS-97.73bn-97.73bn74.77m200.00--0.5466----------0.633----------------------------0.00--------------
BBS-Bioactive Bone Substitutes Oyj0.00-40.70m77.31m----1.23-----0.2926-0.29260.000.26470.00-------32.71-25.12-38.23-28.54-----------28.790.482-------12.64------
SciBase Holding AB (publ)24.15m-55.54m77.89m26.00--2.04--3.22-0.5255-0.52550.22370.24570.30040.78634.33894,592.60-69.07-68.63-90.03-87.7769.2861.28-229.94-300.201.78--0.00--29.9327.50-28.75--5.15--
Bio Vitos Pharma AB2.61m-12.87m81.74m1.00--2.75--31.28-0.1738-0.17380.02160.10120.09780.05645.492,613,400.00-48.17-31.11-49.96-32.9298.14---492.58-1,026.765.48--0.00--126.97--13.64------
Scandinavian Real Heart AB0.00-71.66m82.35m11.00--0.5501-----0.4709-0.47090.000.51440.00----0.00-67.22-24.27-78.30-26.81--832.41---6,070.11---701.980.0945---100.00---385.97---25.76--
PMD Device Solutions AB39.68m-35.45m94.24m1.00------2.37-2.06-2.064.14-5.151.58--30.16---141.30------78.66---89.34--0.0373-1.81----------------
ScandiDos AB60.43m-14.65m96.92m34.00--1.75--1.60-0.3211-0.32111.320.9710.78530.55526.07---19.03-12.60-33.80-21.9378.6982.13-24.24-15.370.9148-11.58-----1.824.36-60.62---19.29--
Clinical Laserthermia Systems AB10.83m-70.90m98.44m7.00--0.9836--9.09-14.73-14.731.935.790.217312.584.86---144.45-123.49-259.50-312.95-392.44-1,084.16-664.90-1,625.032.06-30.970.0094--31.9935.55-12.92--18.26--
Data as of Jul 25 2024. Currency figures normalised to Kontigo Care AB's reporting currency: Swedish Krona SEK

Institutional shareholders

7.02%Per cent of shares held by top holders
HolderShares% Held
PEH Wertpapier AG (Germany)as of 31 Aug 20232.25m7.02%
Data from 28 Jun 2024 - 28 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.